Our top pick for
Syneos Health, Inc is a diagnostics & research business based in the US. Syneos Health shares (SYNH) are listed on the NASDAQ and all prices are listed in US Dollars. Syneos Health employs 24,310 staff and has a trailing 12-month revenue of around USD$4.4 billion.
|52-week range||USD$30.02 - USD$81.35|
|50-day moving average||USD$76.4497|
|200-day moving average||USD$65.1702|
|Wall St. target price||USD$85.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.83|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Syneos Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Syneos Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Syneos Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Syneos Health shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Syneos Health's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.791. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Syneos Health's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Syneos Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$575.2 million.
The EBITDA is a measure of a Syneos Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.4 billion|
|Operating margin TTM||7.99%|
|Gross profit TTM||USD$1 billion|
|Return on assets TTM||2.84%|
|Return on equity TTM||6.15%|
|Market capitalisation||USD$7.9 billion|
TTM: trailing 12 months
There are currently 4.5 million Syneos Health shares held short by investors – that's known as Syneos Health's "short interest". This figure is 6.8% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting Syneos Health shares can be evaluated.
Syneos Health's "short interest ratio" (SIR) is the quantity of Syneos Health shares currently shorted divided by the average quantity of Syneos Health shares traded daily (recently around 646042.56854257). Syneos Health's SIR currently stands at 6.93. In other words for every 100,000 Syneos Health shares traded daily on the market, roughly 6930 shares are currently held short.
However Syneos Health's short interest can also be evaluated against the total number of Syneos Health shares, or, against the total number of tradable Syneos Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syneos Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Syneos Health shares in existence, roughly 40 shares are currently held short) or 0.0717% of the tradable shares (for every 100,000 tradable Syneos Health shares, roughly 72 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syneos Health.
Find out more about how you can short Syneos Health stock.
We're not expecting Syneos Health to pay a dividend over the next 12 months.
Over the last 12 months, Syneos Health's shares have ranged in value from as little as $30.02 up to $81.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syneos Health's is 1.8074. This would suggest that Syneos Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.